Related Experiment Video

Updated: Jun 10, 2026

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
08:38

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

Microscopic polyangiitis

Sharon A Chung1, Philip Seo

  • 1Division of Rheumatology, Department of Medicine, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA, USA.

Rheumatic Diseases Clinics of North America
|August 7, 2010
PubMed

Insights

Microscopic polyangiitis (MPA) is a small-vessel vasculitis often treated with cytotoxic agents and glucocorticoids. Current research seeks alternative therapies to reduce reliance on these potent drugs.

Area of Science:

  • Rheumatology
  • Immunology
  • Pathology

Background:

  • Microscopic polyangiitis (MPA) is a systemic vasculitis distinct from classical periarteritis nodosa.
  • It involves small-caliber blood vessels and is associated with antineutrophil cytoplasmic antibodies.
  • MPA commonly affects the kidneys (glomerulonephritis) and lungs (pulmonary capillaritis).

Purpose of the Study:

  • To review the history, pathogenesis, clinical manifestations, and treatment of microscopic polyangiitis.
  • To highlight current research into alternative treatment strategies for MPA.

Main Methods:

  • Literature review of historical descriptions and recent research.
  • Analysis of pathogenesis, clinical presentation, and treatment modalities.

Main Results:

  • MPA is characterized by small-vessel inflammation and specific autoantibodies.
  • Standard treatment involves cytotoxic agents and high-dose glucocorticoids.
  • Emerging research focuses on minimizing cytotoxic agent exposure.

Conclusions:

  • Understanding MPA's history and pathogenesis is crucial for effective management.
  • Current treatment paradigms are being re-evaluated to improve patient outcomes.
  • Future research aims to develop safer and equally effective MPA therapies.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Retinal Cryo-sections, Whole-Mounts, and Hypotonic Isolated Vasculature Preparations for Immunohistochemical Visualization of Microvascular Pericytes10:46

Retinal Cryo-sections, Whole-Mounts, and Hypotonic Isolated Vasculature Preparations for Immunohistochemical Visualization of Microvascular Pericytes

Published on: October 7, 2018

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...